# Keros Therapeutics

Source: https://onco.cc/companies/keros-therapeutics/  
OnCo record `keros-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Keros Therapeutics is a Massachusetts biotech that works on the TGF-beta family signals controlling blood cell production; its activin ligand trap elritercept treats anaemia in myelodysplastic syndromes and myelofibrosis and was licensed to Takeda.

## Summary

Keros Therapeutics develops medicines that modulate transforming growth factor beta superfamily signalling. Elritercept (KER-050, now TAK-226) is a modified activin receptor type IIA ligand trap that promotes red cell and platelet production; it showed durable transfusion independence in lower-risk myelodysplastic syndromes and myelofibrosis and was licensed to Takeda outside mainland China in December 2024. Cibotercept (KER-012) was studied in pulmonary arterial hypertension and KER-065 is in development for neuromuscular disease.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Keros Therapeutics, Inc.; NASDAQ:KROS
- Tags: drug-maker
- HQ: Lexington, Massachusetts
- Type: biotech
- Website: https://www.kerostx.com/
- Ticker: NASDAQ:KROS

## Sources

- Official website: https://www.kerostx.com/

## Connected records

- drugs: [Elritercept](https://onco.cc/drugs/elritercept/)

---
JSON: https://onco.cc/api/v1/entities/keros-therapeutics.json